Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsSUBCUTANEOUSStandard

RYSTIGGO

ROZANOLIXIZUMAB-NOLI

Standard Dose
280MG/2ML(140MG/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview RYSTIGGO is listed in Drugs@FDA under application 761286 (BLA).

Review priority: STANDARD Marketing status: Prescription Active ingredient ROZANOLIXIZUMAB-NOLI Form and strength INJECTABLE;SUBCUTANEOUS - 280MG/2ML(140MG/ML) Sponsor UCB INC Submission history Latest submission status date: 2025-12-09 00:00:00.

Structured Monograph

Clinical summary

Approval overview RYSTIGGO is listed in Drugs@FDA under application 761286 (BLA). Review priority: STANDARD Marketing status: Prescription Active ingredient ROZANOLIXIZUMAB-NOLI Form and strength INJECTABLE;SUBCUTANEOUS - 280MG/2ML(140MG/ML) Sponsor UCB INC Submission history Latest submission status date: 2025-12-09 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.